Japan Lyxumia nod ups GLP-1 stakes
This article was originally published in Scrip
Executive Summary
Sanofi's glucagon-like peptide-1 receptor agonist Lyxumia (lixisenatide; licensed from Zealand Pharma) has been approved in Japan, where it has become the first product in its class to be cleared for use in combination with basal insulin for the treatment of type 2 diabetes.